NYXOAH
Nyxoah is a health-technology company focused on the development and commercialization of innovative solutions and services to treat sleep disordered breathing conditions. Nyxoah's lead solution platform is based on the Genio® system, a validated, user-centered, next generation neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
NYXOAH
Industry:
Health Care Medical Medical Device Neuroscience
Founded:
2009-01-01
Address:
Mont-saint-guibert, Brabant Wallon, Belgium
Country:
Belgium
Website Url:
http://www.nyxoah.com
Total Employee:
11+
Status:
Active
Contact:
(322)612-1755
Total Funding:
66 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible LetsEncrypt Nginx Cloudflare JS YouTube Facebook Custom Audiences Apache 2.4 PostalAddress Schema Ubuntu
Similar Organizations
CeQur
CeQur develops and commercializes insulin delivery systems, giving people with type 2 diabetes freedom from multiple daily injections.
InTouch Health
InTouch Health is the leader in Acute Care Telemedicine solutions.
Minerva Surgical
Minerva Surgical is a medical device start-up company developing medical devices for women’s healthcare.
MIVI Neuroscience
MIVI Neuroscience focuses on developing and commercializing clinical solutions for neurointerventional procedures.
NinePoint Medical
NinePoint Medical is a transformational medical device company developing innovative, real-time, in vivo pathology devices.
Pulse Biosciences
Pulse Biosciences is a medical device company that engages in the research and development, and commercialization of CellFX system.
SceneRay
SceneRay is a medical device company dedicated to the design, Development, and distribution of neuromodulation devices.
Senseonics
Senseonics is a medical device startup company that focuses on the design, development, and commercialization of glucose monitoring systems.
Sinocelltech
Sinocelltech is a biotech company that develops and manufactures recombinant proteins, monoclonal antibodies, and vaccines.
Vascular Flow Technologies
Vascular Flow Tech focuses on research, development and commercialization of vascular devices based on new understanding of blood flow.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
ResMed
ResMed investment in Corporate Round - Nyxoah
Cochlear
Cochlear investment in Corporate Round - Nyxoah
Cochlear
Cochlear investment in Series C - Nyxoah
S.R.I.W.
S.R.I.W. investment in Series B - Nyxoah
Gilde Healthcare
Gilde Healthcare investment in Series B - Nyxoah
Viralety Ventures
Viralety Ventures investment in Series A - Nyxoah
Official Site Inspections
http://www.nyxoah.com Semrush global rank: 3.86 M Semrush visits lastest month: 3.37 K
- Host name: ec2-18-192-87-180.eu-central-1.compute.amazonaws.com
- IP address: 18.192.87.180
- Location: Frankfurt am Main Germany
- Latitude: 50.1188
- Longitude: 8.6843
- Timezone: Europe/Berlin
- Postal: 60313
More informations about "Nyxoah"
| Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA).See details»
Management Team - Nyxoah
Olivier Taelman is an experienced MedTech leader, joining Nyxoah in July 2019 as Chief Operating and Commercial Officer and subsequently being appointed as CEO in November …See details»
Board of Directors - Nyxoah
Olivier Taelman is an experienced MedTech leader, joining Nyxoah in July 2019 as Chief Operating and Commercial Officer and subsequently being appointed as CEO in November 2019. Olivier spent 7 years in commercial healthcare at Eli …See details»
About Nyxoah - Nyxoah Investors
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA).See details»
Nyxoah - Crunchbase Company Profile & Funding
Nyxoah is a medical device company focused on the development and commercialization of a hypoglossal nerve stimulation (HGNS) therapy. View contacts for Nyxoah to access new leads and connect with decision-makers.See details»
Nyxoah Announces 2024 Strategic Priorities | Nyxoah
Jan 17, 2024 · Accelerate investments in the U.S. commercial organization in preparation for a late 2024 launch. Recently hired Francis Kim as Chief Regulatory and Quality Officer and …See details»
The path to restful nights - Nyxoah Investors
To obtain a copy of this Annual Report free of charge, please contact: [email protected]. An electronic version of this Annual Report is available on the Company website: …See details»
Annual report 2022 The path to restful - Nyxoah Investors
To obtain a copy of this Annual Report free of charge, please contact: [email protected]. An electronic version of this Annual Report is available on the Company website: https://investors. …See details»
Nyxoah Announces 2024 Strategic Priorities - Yahoo Finance
Jan 17, 2024 · Accelerate investments in the U.S. commercial organization in preparation for a late 2024 launch. Recently hired Francis Kim as Chief Regulatory and Quality Officer and …See details»
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA).See details»
Nyxoah Aims to Replicate its European Success …
Jan 18, 2024 · Nyxoah SA, maker of the CE-marked Genio neurostimulator for the treatment of obstructive sleep apnea (OSA), outlined its strategic goals for 2024, focusing on pivotal study completions, regulatory submissions, and …See details»
Nyxoah Reports Full Year 2021 Operating and Financial
Mar 24, 2022 · Nyxoah’s financial report for the full year 2021, including details of the audited consolidated results, are available on the investor page of Nyxoah’s website...See details»
Nyxoah Reports Full Year 2020 Results
Apr 9, 2021 · Mont-Saint-Guibert, Belgium – 9 April 2021 – Nyxoah SA (Euronext Brussels: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the …See details»
Nyxoah Announces 2024 Strategic Priorities - Nasdaq
Jan 17, 2024 · Mont-Saint-Guibert, Belgium – January 17, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical …See details»
Nyxoah Reports Third Quarter Financial and Operating Results
Raised €24.6 million through an ATM program from a single U.S. healthcare-dedicated fundproviding incremental flexibility as we shift into U.S. commercialization and extending cash …See details»
Obstructive Sleep Apnea Treatment | Genio by Nyxoah
Genio is a treatment for obstructive sleep apnea (OSA). It is indicated for patients who cannot tolerate or have failed continuous positive airway pressure (CPAP) therapy. Genio uses …See details»
Nyxoah Reports Second Quarter and First Half 2024 Financial and ...
Aug 6, 2024 · Strengthening U.S. commercial organization, highlighted by the appointments of Scott Holstine as Chief Commercial Officer and key sales, marketing and market access …See details»
Nyxoah Raises $27 Million through its At-the-Market Offering
Oct 7, 2024 · Nyxoah Raises $27 Million through its At-the-Market Offering. Investment by a new U.S.-based healthcare investor, strengthening the balance sheet and reinforcing U.S. focus.See details»
TABLE OF CONTENTS - Nyxoah Investors
In June 2020, the United States Food and Drug Administration ("FDA") approved Nyxoah IDE application, allowing the Company to commence its pivotal DREAM trial of the Genio® system.See details»
Nyxoah Announces Launch of Proposed Public Offering
Jun 25, 2021 · Mont-Saint-Guibert, Belgium – June 25, 2021, 12:30 pm CET / 6:30 am ET – Nyxoah SA (Euronext Brussels: NYXH) (“Nyxoah” or the “Company”), a medical technology …See details»